Skip to main content

Poseida Therapeutics, Inc.

PSTXDelisted Jan 8, 2025
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001661460

Poseida Therapeutics, Inc. was delisted on Jan 8, 2025; its insiders filed their last Form 4 on Jan 10, 2025; 116 institutions reported holding it in 13F filings for Q4 2024, worth $519.2M in total; no superinvestor held it.

Q1 2024 vs. Q4 2023

How the institutions holding Poseida Therapeutics, Inc. changed between Q4 2023 and Q1 2024.

All holders in Q1 2024All holders in Q4 2023

13F holders of PSTX: Q4 2023 compared with Q1 2024
MeasureQ4 2023Q1 2024Change
Holders91910
Shares45.3M52.9M+7.52M (+16.6%)
Value$152.4M$168.6M+$16.3M (+10.7%)

New holders (14)

Institutions that held Poseida Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.

Institutions new to PSTX in Q1 2024
InstitutionSharesValue% of portfolio
Boxer Capital, LLC4,475,000$14.3M0.71%
Octagon Capital Advisors LP736,000$2.35M0.29%
Wellington Management Group LLP356,896$1.14M0.00%
Artia Global Partners LP86,002$274.3K0.07%
Man Group plc79,637$254.0K0.00%
ExodusPoint Capital Management, LP76,686$245.0K0.00%
Citadel Advisors LLC64,424$205.5K0.00%
Balyasny Asset Management LLC56,837$181.3K0.00%
Russell Investments Group, Ltd.34,503$110.1K0.00%
Deutsche Bank AG29,651$94.6K0.00%
Palumbo Wealth Management LLC26,068$83.2K0.04%
Bayesian Capital Management, LP10,200$32.5K0.00%
US Bancorp5,200$16.6K0.00%
Nelson, Van Denburg & Campbell Wealth Management Group, LLC13$410.00%

Sold out (14)

Institutions that held Poseida Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.